Loading
IARC estimates 8,222 new cancer cases and 4,841 cancer deaths in Tajikistan in 2024; the commonest new cancers are stomach, colorectum and breast. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Stomach | 1,297 | 18.7 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 841 | 11.2 | Colorectal cancer |
| Breast | 663 | 14.8 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 447 | 10.1 | Cervical cancer |
| Brain, central nervous system | 431 | 4.8 | Glioma & glioblastoma |
| Trachea, bronchus and lung | 356 | 5.0 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Corpus uteri | 346 | 8.0 | Endometrial cancer |
| Liver and intrahepatic bile ducts | 318 | 4.5 | Hepatocellular carcinoma |
| Prostate | 313 | 11.4 | Prostate cancer |
| Kidney | 221 | 2.7 | Renal cell carcinoma |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Stomach | 1,051 | 15.7 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 384 | 5.4 | Colorectal cancer |
| Trachea, bronchus and lung | 324 | 4.7 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Brain, central nervous system | 319 | 3.8 | Glioma & glioblastoma |
| Liver and intrahepatic bile ducts | 284 | 4.1 | Hepatocellular carcinoma |
| Breast | 278 | 6.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 244 | 5.7 | Cervical cancer |
| Prostate | 180 | 6.7 | Prostate cancer |
| Oesophagus | 129 | 2.0 | Oesophageal cancer |
| Leukaemia | 120 | 1.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
No trial record in OnCo lists a site in Tajikistan. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Tajikistan.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Tajikistan is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Tajikistan is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.